Nintedanib 1a Pharma (Nintedanib Esylate)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—preventing downstream signaling that drives fibroblast activation, angiogenesis and tissue remodeling. By inhibiting these pathways, it reduces the formation of fibrotic tissue and can limit tumor‑related vascular growth.

The exact dose of Nintedanib is set by the prescribing clinician based on the approved indication, patient weight, renal and hepatic function, and any concomitant medications. Dosing recommendations are provided in the product labeling, but the final regimen is individualized by the treating physician.

Safety of Nintedanib in pregnancy and lactation has not been established. The product is classified as contraindicated in pregnancy because potential fetal harm cannot be ruled out, and breastfeeding is not recommended while receiving therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative antifibrotic is pirfenidone. Both agents slow disease progression in idiopathic pulmonary fibrosis, but they differ in target pathways—pirfenidone modulates cytokine production while Nintedanib blocks multiple tyrosine kinases. Their safety profiles also vary; for example, Nintedanib is more frequently associated with diarrhea, whereas pirfenidone often causes photosensitivity.

Nintedanib oral capsules should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Nintedanib is taken orally as a capsule, usually with food to reduce gastrointestinal discomfort. The capsule is swallowed whole with a glass of water and should not be crushed, chewed, or opened. Administration timing follows the dosing schedule prescribed by the treating physician.

Serious risks include liver injury (hepatotoxicity), cardiovascular events such as arterial thromboembolism or myocardial infarction, and severe bleeding. Patients should be monitored regularly for liver enzyme elevations, signs of cardiovascular compromise, and any unexpected hemorrhagic symptoms.

Nintedanib is contraindicated in patients with known hypersensitivity to the drug or its excipients, in pregnant women, and in individuals with severe hepatic impairment. Caution is also advised for patients with a history of significant cardiovascular disease, active bleeding, or uncontrolled gastrointestinal disorders.